Author: Bravo, Jack P.K.; Dangerfield, Tyler L.; Taylor, David W.; Johnson, Kenneth A.
Title: Remdesivir is a delayed translocation inhibitor of SARS CoV-2 replication Cord-id: orleukvu Document date: 2021_1_28
ID: orleukvu
Snippet: Remdesivir is a nucleoside analog approved by the FDA for treatment of COVID-19. Here, we present a 3.9-Ã…-resolution cryoEM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of three copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of three bases following RMP, resulting in delayed chain termination, which can gui
Document: Remdesivir is a nucleoside analog approved by the FDA for treatment of COVID-19. Here, we present a 3.9-Ã…-resolution cryoEM reconstruction of a remdesivir-stalled RNA-dependent RNA polymerase complex, revealing full incorporation of three copies of remdesivir monophosphate (RMP) and a partially incorporated fourth RMP in the active site. The structure reveals that RMP blocks RNA translocation after incorporation of three bases following RMP, resulting in delayed chain termination, which can guide the rational design of improved antiviral drugs.
Search related documents:
Co phrase search for related documents- active site and additional analysis: 1, 2
- active site and adenosine analog: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date